BG106539A - Bicyclic androgen and progesterone receptor modulator compounds and methods - Google Patents
Bicyclic androgen and progesterone receptor modulator compounds and methodsInfo
- Publication number
- BG106539A BG106539A BG106539A BG10653902A BG106539A BG 106539 A BG106539 A BG 106539A BG 106539 A BG106539 A BG 106539A BG 10653902 A BG10653902 A BG 10653902A BG 106539 A BG106539 A BG 106539A
- Authority
- BG
- Bulgaria
- Prior art keywords
- methods
- androgen
- bicyclic
- compounds
- receptor modulator
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15098799P | 1999-08-27 | 1999-08-27 | |
PCT/US2000/023585 WO2001016108A2 (en) | 1999-08-27 | 2000-08-25 | Bicyclic androgen and progesterone receptor modulator compounds and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
BG106539A true BG106539A (en) | 2002-10-31 |
Family
ID=22536851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG106539A BG106539A (en) | 1999-08-27 | 2002-03-21 | Bicyclic androgen and progesterone receptor modulator compounds and methods |
Country Status (19)
Country | Link |
---|---|
US (4) | US6566372B1 (pt) |
EP (1) | EP1212303A2 (pt) |
JP (1) | JP2003508387A (pt) |
KR (1) | KR20020040791A (pt) |
CN (3) | CN1262540C (pt) |
AU (1) | AU782647B2 (pt) |
BG (1) | BG106539A (pt) |
BR (1) | BR0013653A (pt) |
CA (1) | CA2384435A1 (pt) |
CZ (1) | CZ2002709A3 (pt) |
HU (1) | HUP0204337A3 (pt) |
IL (1) | IL148046A0 (pt) |
MX (2) | MXPA02002027A (pt) |
NO (1) | NO20020912L (pt) |
PL (1) | PL354410A1 (pt) |
SK (1) | SK2742002A3 (pt) |
TR (1) | TR200200508T2 (pt) |
WO (1) | WO2001016108A2 (pt) |
ZA (1) | ZA200201053B (pt) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
AT407876B (de) * | 1999-04-30 | 2001-07-25 | Georg Dr Uray | Lumineszierende 4-trifluormethyl-2-chinolinone mit langwelliger uv-absorption und ihre verwendung |
US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6391907B1 (en) * | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
CZ2002711A3 (cs) * | 1999-08-27 | 2003-11-12 | Ligand Pharmaceuticals Incorporated | Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
EP1299094A2 (en) * | 2000-06-28 | 2003-04-09 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
US7026484B2 (en) * | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
US7214690B2 (en) * | 2001-02-23 | 2007-05-08 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods |
US6858592B2 (en) | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
US7041280B2 (en) | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
WO2003011824A1 (en) | 2001-07-31 | 2003-02-13 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
JP2003073374A (ja) * | 2001-08-31 | 2003-03-12 | Kaken Pharmaceut Co Ltd | 2環性芳香族アミン誘導体 |
KR20040086262A (ko) * | 2002-01-09 | 2004-10-08 | 트라이던트 사이언스 엘엘씨 | 안드로겐 수용체 차단 화합물 |
PL209872B1 (pl) | 2002-03-27 | 2011-10-31 | Glaxo Group Ltd | Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja |
DE60303376T2 (de) | 2002-05-13 | 2006-11-16 | F. Hoffmann-La Roche Ag | Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
KR20050013627A (ko) * | 2002-06-25 | 2005-02-04 | 와이어쓰 | Pr 조절제로서의 사이클로티오카바메이트 유도체 및피부 질환을 치료하기 위한 이의 용도 |
WO2004000227A2 (en) * | 2002-06-25 | 2003-12-31 | Wyeth | Use of thio-oxindole derivatives in treatment of skin disorders |
MXPA04012419A (es) * | 2002-06-25 | 2005-04-19 | Wyeth Corp | Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con la hormona. |
HK1055058A2 (en) * | 2002-10-11 | 2003-12-05 | Ligand Pharm Inc | 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
CA2501833A1 (en) | 2002-10-11 | 2004-04-22 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
BRPI0406778A (pt) | 2003-01-17 | 2006-01-17 | Warner Lambert Co | Antagonistas de receptores de androgênio |
JP2006515606A (ja) * | 2003-01-17 | 2006-06-01 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | アンドロゲン受容体アンタゴニスト |
BRPI0407354A (pt) * | 2003-02-11 | 2006-01-10 | Warner Lambert Co | Derivados de uréia e tiouréia |
CA2514244A1 (en) | 2003-02-11 | 2004-08-26 | Warner-Lambert Company Llc | Benzyl urea and thiourea derivatives useful as androgen antagonists |
US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
US7098340B2 (en) * | 2003-05-14 | 2006-08-29 | Warner Lambert Company Llc | Benzyl sulfonamide derivatives |
US7105467B2 (en) * | 2003-07-08 | 2006-09-12 | Pharmacore, Inc. | Nickel catalyzed cross-coupling reactions between organomagnesium compounds and anisole derivatives |
DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
BRPI0413820A (pt) * | 2003-08-22 | 2006-10-24 | Ligand Pharm Inc | derivados de 6-cicloamino-2-quinolinona como compostos moduladores de receptor de androgênio |
US7247625B2 (en) | 2003-10-09 | 2007-07-24 | Wyeth | 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators |
WO2005051298A2 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
US7928104B2 (en) * | 2003-11-20 | 2011-04-19 | Dominique Jean-Pierre Mabire | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
WO2005054201A1 (en) | 2003-11-20 | 2005-06-16 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
CN1890224B (zh) * | 2003-12-05 | 2011-06-08 | 詹森药业有限公司 | 用作聚(adp-核糖)聚合酶抑制剂的6-取代的2-喹啉酮和2-喹喔啉酮 |
WO2005058847A1 (en) | 2003-12-09 | 2005-06-30 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives and uses thereof |
SG151250A1 (en) * | 2003-12-10 | 2009-04-30 | Janssen Pharmaceutica Nv | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
US7105707B2 (en) * | 2003-12-17 | 2006-09-12 | Pharmacore, Inc. | Process for preparing alkynyl-substituted aromatic and heterocyclic compounds |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7311737B2 (en) | 2004-02-27 | 2007-12-25 | L'oreal | Secondary para-phenylenediamine compounds comprising N-alkylfluorine, dye compositions comprising them and processes of dyeing therewith |
FR2866881B1 (fr) * | 2004-02-27 | 2007-10-05 | Oreal | Para-phenylenediamines secondaires n-alkylfluorees, composition tinctoriale les comprenant, procedes et utilisations |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
WO2005090282A1 (en) | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
US7582755B2 (en) * | 2004-04-27 | 2009-09-01 | Wyeth | Cyanopyrrole-containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same |
UA88012C2 (uk) | 2004-06-30 | 2009-09-10 | Янссен Фармацевтика Н.В. | Похідні хіназоліндіону як інгібітори parp |
ATE498613T1 (de) * | 2004-06-30 | 2011-03-15 | Janssen Pharmaceutica Nv | Chinazolinonderivate als parp-hemmer |
EA014955B1 (ru) * | 2004-06-30 | 2011-04-29 | Янссен Фармацевтика Н. В. | Производные фталазина в качестве ингибиторов parp |
WO2006077821A1 (ja) * | 2005-01-19 | 2006-07-27 | Dainippon Sumitomo Pharma Co., Ltd. | アルドステロン受容体調節剤としての芳香族スルホン化合物 |
MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
MX2007014501A (es) * | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos novedosos que contienen acido fosfinico. |
CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
EP1891067B1 (en) * | 2005-06-17 | 2016-01-13 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
AR057656A1 (es) * | 2005-07-01 | 2007-12-12 | Ligand Pharm Inc | Compuestos moduladores de receptores de androgeno y metodods relacionados |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
AU2006282767A1 (en) * | 2005-08-26 | 2007-03-01 | The Regents Of The University Of California | Non-steroidal antiandrogens |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
AR056893A1 (es) * | 2005-12-28 | 2007-10-31 | Takeda Pharmaceutical | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
MX2009003874A (es) * | 2006-10-12 | 2009-04-22 | Xenon Pharmaceuticals Inc | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. |
WO2008060789A2 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
WO2008046049A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
EP2134691B1 (en) | 2007-03-08 | 2012-01-25 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as parp and tank inhibitors |
US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
JP2009079039A (ja) * | 2007-09-05 | 2009-04-16 | Sumitomo Chemical Co Ltd | クマリン化合物及びその用途 |
JP2009062300A (ja) * | 2007-09-05 | 2009-03-26 | Sumitomo Chemical Co Ltd | クマリン化合物及びその用途 |
JP2009084269A (ja) * | 2007-09-05 | 2009-04-23 | Sumitomo Chemical Co Ltd | クマリン化合物及びその用途 |
JP2009079037A (ja) * | 2007-09-06 | 2009-04-16 | Sumitomo Chemical Co Ltd | アミロイドβタンパク質の蓄積を抑制するための医薬組成物 |
PL2215075T3 (pl) * | 2007-10-26 | 2014-04-30 | Janssen Pharmaceutica Nv | Pochodne chinolinonu jako inhibitory PARP |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
CA2709677C (en) * | 2007-12-21 | 2017-03-14 | Lin Zhi | Selective androgen receptor modulators (sarms) and uses thereof |
WO2009118382A1 (en) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
AU2009228945B2 (en) * | 2008-03-27 | 2013-05-02 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US8729097B2 (en) | 2008-10-06 | 2014-05-20 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders |
EP2350091B1 (en) * | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
SG10201703086VA (en) | 2008-10-17 | 2017-05-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their use as therapeutic agents |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
SG172986A1 (en) | 2009-02-10 | 2011-08-29 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
WO2011029782A1 (en) | 2009-09-11 | 2011-03-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
RU2544852C2 (ru) * | 2009-10-14 | 2015-03-20 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
US9504671B2 (en) | 2010-02-26 | 2016-11-29 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
WO2012047617A1 (en) * | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Selective androgen receptor modulators |
US9802948B2 (en) | 2010-10-13 | 2017-10-31 | Trustees Of Boston Univeristy | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics |
WO2012050985A1 (en) | 2010-10-13 | 2012-04-19 | Trustees Of Boston University | Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics |
US9815845B2 (en) | 2010-10-13 | 2017-11-14 | Trustees Of Boston University | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics |
JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
US9428460B2 (en) | 2012-06-26 | 2016-08-30 | Bayer Pharma Aktiengesellschaft | N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products |
CN103127112A (zh) * | 2013-02-27 | 2013-06-05 | 江苏先声药物研究有限公司 | 一类喹啉酮衍生物在肿瘤治疗中的应用 |
WO2014143617A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Women's Health, Inc. | Deuterium-enriched tanaproget and processes for its preparation |
US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
NO2699580T3 (pt) | 2014-01-24 | 2018-02-24 | ||
KR102193461B1 (ko) * | 2014-04-24 | 2020-12-21 | 동아에스티 주식회사 | 퀴놀린계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제 |
KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
EP3177593A1 (en) * | 2014-08-06 | 2017-06-14 | Novartis AG | Quinolone derivatives as antibacterials |
MA41140A (fr) * | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
KR102600115B1 (ko) | 2017-06-05 | 2023-11-09 | 바이킹 테라퓨틱스 인코포레이티드 | 섬유증 치료를 위한 조성물 |
EP3768690A4 (en) | 2018-03-22 | 2021-11-24 | Viking Therapeutics, Inc. | CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND |
EP3829583A4 (en) | 2018-08-02 | 2022-07-27 | Trustees of Boston University | LATE SV40 FACTOR (SPF) INHIBITORS |
US11242353B2 (en) | 2020-01-24 | 2022-02-08 | Trustees Of Boston University | Heterocyclic LSF inhibitors and their uses |
AU2021267373A1 (en) | 2020-05-06 | 2022-12-08 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
WO2022051388A2 (en) | 2020-09-01 | 2022-03-10 | Trustees Of Boston University | Quinolin-2(1h)-one inhibitors of late sv40 factor |
WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (173)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE25586E (en) * | 1951-05-08 | 1964-06-02 | So jxnh o oh | |
US3615521A (en) * | 1968-10-01 | 1971-10-26 | Eastman Kodak Co | Photographic compositions and processes-a |
CH590274A5 (pt) | 1970-03-16 | 1977-07-29 | Hoffmann La Roche | |
DE2015186A1 (de) * | 1970-03-28 | 1971-10-21 | Henkel & Cie, GmbH, 4000 Düsseldorf | Zur Verwendung in bactericiden Textilbehandlungsmitteln geeignete Aufhellerkombination |
DE2038106A1 (de) | 1970-07-31 | 1972-02-10 | Henkel & Cie Gmbh | Aktivatoren fuer Perverbindungen |
GB1379387A (en) | 1970-12-11 | 1975-01-02 | Agfa Gevaert | Photoconductive recording materials |
US3979394A (en) | 1970-12-11 | 1976-09-07 | Agfa-Gevaert N.V. | Duplo quinoline compounds |
DE2126811A1 (en) | 1971-05-29 | 1972-12-14 | Basf Ag | Fluorescent pigments dyes - of the coumarin series for synthetic fibres and plastics |
GB1400993A (en) | 1971-11-10 | 1975-07-16 | Agfa Gevaert | Electrophotographic material |
US3847988A (en) | 1971-12-23 | 1974-11-12 | Schering Corp | Substituted imidates |
BE795696A (nl) | 1972-02-28 | 1973-08-21 | Agfa Gevaert Nv | Voor warmte gevoelige materialen |
DE2334738A1 (de) * | 1973-07-09 | 1975-01-30 | Henkel & Cie Gmbh | Haarfaerbemittel |
US3936461A (en) | 1973-09-24 | 1976-02-03 | Warner-Lambert Company | Substituted 4-benzylquinolines |
US3993656A (en) | 1974-11-19 | 1976-11-23 | Merck & Co., Inc. | 1,8-Naphthyridine compounds |
FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
US4138490A (en) | 1975-03-20 | 1979-02-06 | Imperial Chemical Industries Limited | Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives |
IE43079B1 (en) * | 1975-03-20 | 1980-12-17 | Ici Ltd | Quinolone derivatives |
SU555119A1 (ru) | 1975-05-19 | 1977-04-25 | Предприятие П/Я Г-4913 | Вулканизуема резинова смесь на основе полиизопренового каучука |
LU77254A1 (pt) | 1977-05-04 | 1979-01-18 | ||
US4326055A (en) | 1977-12-22 | 1982-04-20 | Hoffmann-La Roche Inc. | Stilbene derivatives |
JPS54154797A (en) | 1978-05-25 | 1979-12-06 | Eisai Co Ltd | Benzimidazoquinolizine derivative and antibacterials comprising it |
US4234589A (en) | 1979-09-24 | 1980-11-18 | E. R. Squibb & Sons, Inc. | Imidazolylethoxymethyl derivatives of 1,3-dioxolo quinolines |
JPS5777676A (en) | 1980-10-31 | 1982-05-15 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
DE3202100A1 (de) | 1982-01-23 | 1983-08-04 | Basf Ag, 6700 Ludwigshafen | Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
US4534979A (en) | 1982-06-28 | 1985-08-13 | Usv Pharmaceutical Corp. | Polyene compounds useful in the treatment of psoriasis and allergic responses |
ATE28864T1 (de) * | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
US4427654A (en) | 1982-07-27 | 1984-01-24 | University Of Delaware | Wound healing compositions and formulations |
US4505852A (en) | 1982-11-29 | 1985-03-19 | Enzyme Systems Products | 7-Amino-4-trifluoromethylquinolone derived substrates and method for determining enzymes and inhibitors |
US4539134A (en) | 1982-12-02 | 1985-09-03 | Halliburton Company | Methods and cleaning compositions for removing organic materials from metallic surfaces |
JPS6056985A (ja) | 1983-09-08 | 1985-04-02 | Sankyo Co Ltd | クマリン誘導体 |
PT79699B (en) | 1983-12-22 | 1986-12-10 | Pfizer | Process for preparing quinolone inotropic agents |
GB8406000D0 (en) | 1984-03-07 | 1984-04-11 | Ici Plc | Olefine derivatives |
NZ212209A (en) | 1984-05-29 | 1988-08-30 | Pfizer | Quinolone derivatives and pharmaceutical compositions |
US4783549A (en) | 1984-09-05 | 1988-11-08 | L'oreal | Benzonorbornene derivatives, processes for their preparation and medicinal and cosmetic compositions containing them |
DE3434944A1 (de) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | L-substituierte tetralinderivate, ihre herstellung und verwendung |
FR2580277B1 (fr) | 1985-04-15 | 1988-06-10 | Oreal | Nouveaux derives naphtaleniques a action retinoique, le ur procede de preparation et compositions medicamenteuse et cosmetique les contenant |
LU86022A1 (fr) | 1985-07-25 | 1987-02-04 | Cird | Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique |
JPS62215581A (ja) | 1986-03-18 | 1987-09-22 | Koichi Shiyudo | フラボンカルボン酸誘導体 |
DE3609804A1 (de) | 1986-03-22 | 1987-09-24 | Basf Ag | Thiazolyl-cyan-cumarine und ihre verwendung zur flaechenmaessigen konzentrierung von licht |
FR2601670B1 (fr) | 1986-07-17 | 1988-10-07 | Cird | Nouveaux derives bicycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
FR2605626B1 (fr) | 1986-10-27 | 1989-06-02 | Oreal | Nouveaux derives aromatiques bicycliques, leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire |
US5081242A (en) | 1986-12-22 | 1992-01-14 | Ortho Pharmaceutical Corporation | 6-benzoxazinyl- and 6-benzothiazinyl 2,3,4,5-tetrahydropyridazin-3-ones |
GB8630702D0 (en) | 1986-12-23 | 1987-02-04 | Wellcome Found | Quinoline compound |
FR2614618B1 (fr) | 1987-04-30 | 1989-07-07 | Cird | Derives heterocycliques polycycliques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire |
US7560273B2 (en) * | 2002-07-23 | 2009-07-14 | Applied Biosystems, Llc | Slip cover for heated platen assembly |
EP0303418A3 (en) | 1987-08-11 | 1990-11-07 | Smithkline Beecham Laboratoires Pharmaceutiques | Substituted indolones, useful in the treatment of heart or asthmatic diseases |
LU87040A1 (fr) | 1987-11-04 | 1989-06-14 | Oreal | Esters aromatiques polycycliques d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant |
US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
WO1989007441A1 (en) | 1988-02-10 | 1989-08-24 | The Regents Of The University Of California | 6-amino-1,2-benzopyrone antitumorigenic agents and method |
DE3810706A1 (de) | 1988-03-25 | 1989-10-05 | Schering Ag | Substituierte cumarinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider wirkung |
DE68916592T2 (de) | 1988-06-23 | 1994-12-01 | Agfa Gevaert Nv | Für elektrophotographische Zwecke geeignetes photoempfindliches Aufzeichnungsmaterial. |
GB8820174D0 (en) | 1988-08-25 | 1988-09-28 | Wellcome Found | Quinoline compound |
US5091528A (en) | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
DE4036779A1 (de) | 1990-11-17 | 1992-05-21 | Basf Ag | Verwendung von arylpolyencarbonsaeuren und ihren derivaten als lichtschutzmittel in kosmetischen zubereitungen |
US5147844A (en) | 1991-06-14 | 1992-09-15 | Eastman Kodak Company | Mixture on cyan and yellow dyes to form a green hue for color filter array element |
FR2683818B1 (fr) | 1991-11-14 | 1993-12-31 | Adir Cie | Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5808139A (en) | 1992-04-21 | 1998-09-15 | Ligand Pharmaceuticals Incorporated | Non-steroid progesterone receptor agonist and antagonist and compounds and methods |
ATE307795T1 (de) | 1992-04-22 | 2005-11-15 | Ligand Pharm Inc | Verbindungen mit retinoid x rezeptorselektivität |
WO1993022317A1 (en) | 1992-05-01 | 1993-11-11 | Kowa Co., Ltd. | Quinoline derivative or salt thereof and remedy for cardiac diseases containing the same |
CA2093577C (en) | 1992-05-07 | 2006-01-03 | Michael Klaus | Alkyl or alkoxy substituted s-heterocyclic retinoids |
JP2594409B2 (ja) | 1992-09-29 | 1997-03-26 | アディール エ コンパニー | トリエン側鎖を有する新規クロメン化合物 |
JPH08506323A (ja) | 1992-11-25 | 1996-07-09 | ラ ホヤ キャンサー リサーチ ファウンデーション | Rxrホモダイマー形成ならびに架橋二環式芳香族化合物および調節遺伝子発現におけるそれらの使用 |
BR9307784A (pt) | 1993-01-11 | 1995-11-14 | Ligand Pharm Inc | Compostos tendo seletivamente para receptores de retinóide X |
WO1994015901A1 (en) | 1993-01-11 | 1994-07-21 | Ligand Pharmaceuticals Inc. | Compounds having selectivity for retinoid x receptors |
US5455265A (en) | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US5399586A (en) | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
US5567855A (en) | 1994-04-21 | 1996-10-22 | Ligand Pharmaceuticals Incorporated | Methods for stereospecific synthesis of polyene aldehydes |
US5677336A (en) | 1993-10-21 | 1997-10-14 | Ligand Pharmaceuticals Incorporated | Non-steroid androgen receptor antagonist compounds and methods |
US5506102A (en) | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
WO1995024394A1 (en) | 1994-03-08 | 1995-09-14 | Takeda Chemical Industries, Ltd. | Quinoline or quinazoline derivatives as anti-inflammatory agents, in particular for treating arthritis |
FR2719041B1 (fr) | 1994-04-26 | 1996-05-31 | Cird Galderma | Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
JP2848964B2 (ja) | 1994-08-10 | 1999-01-20 | エフ・ホフマン−ラ ロシュ アーゲー | レチノイン酸x受容体リガンド |
US5977125A (en) | 1994-10-31 | 1999-11-02 | Eisai Co., Ltd. | Mono-or polyenic carboxylic acid derivatives |
IL116259A (en) | 1994-12-19 | 2000-07-16 | American Cyanamid Co | Analogs of 9-cis retinoic acid and their use |
US5968908A (en) | 1994-12-19 | 1999-10-19 | American Cyanamid Company | Restricted 9-cis retinoids |
US5693646A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
NZ300739A (en) | 1994-12-22 | 2000-05-26 | Ligand Pharm Inc | Steroid receptor modulator compounds |
US6696459B1 (en) * | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
MX9704878A (es) | 1994-12-30 | 1997-11-29 | Ligand Pharm Inc | Nuevos compuestos retinoides trienoicos y metodos de uso. |
US6083977A (en) | 1994-12-30 | 2000-07-04 | Ligand Pharmaceuticals Incorporated | Trienoic retinoid compounds and methods |
DK0835258T3 (da) | 1995-06-21 | 2003-02-03 | Sod Conseils Rech Applic | Hidtil ukendte camptothecin-analoger, fremgangsmåder til fremstilling heraf, anvendelse heraf som lægemidler og farmaceutiske præparater indeholdende disse |
JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
KR100625255B1 (ko) | 1995-10-06 | 2008-01-30 | 리간드 파마슈티칼스 인코포레이티드 | 다이머-선택적rxr변조물질및그의사용방법 |
US6017924A (en) | 1996-06-27 | 2000-01-25 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
EP0918774B9 (en) | 1996-06-27 | 2002-04-10 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
FR2752837B1 (fr) | 1996-09-02 | 1999-11-12 | Cird Galderma | Nouveaux composes modulateurs des recepteurs hormonaux, les compositions les comprenant et leur utilisation en therapie |
DE19648559B4 (de) | 1996-11-23 | 2009-01-29 | Wabco Gmbh | Verfahren zur Geschwindigkeitsregelung für ein Fahrzeug im Gefälle |
US6005007A (en) | 1997-07-18 | 1999-12-21 | Farmer; Luc J. | Retinoids, methods for their production and use |
WO1999024024A2 (en) | 1997-11-12 | 1999-05-20 | F. Hoffmann-La Roche Ag | Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists |
US6380207B2 (en) * | 1998-02-13 | 2002-04-30 | Abbott Laboratories | Glucocortiocoid-selective antiinflammatory agents |
US6001846A (en) | 1998-02-17 | 1999-12-14 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
JPH11242304A (ja) | 1998-02-26 | 1999-09-07 | Konica Corp | 熱現像感光材料 |
EP1056775B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
EP1077919A1 (en) | 1998-05-11 | 2001-02-28 | Novo Nordisk A/S | New compounds, their preparation and use |
US6093825A (en) | 1998-05-27 | 2000-07-25 | American Home Products | Methods for preparation of 1,2-dihydroquinolines |
US6093826A (en) | 1998-06-08 | 2000-07-25 | Ligand Pharmaceuticals Incorporated | Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines |
PT1098972E (pt) * | 1998-07-22 | 2010-12-14 | Smithkline Beecham Ltd | Proteína semelhante a proteína especificamente neuroendócrina e adnc codificante |
AU754529B2 (en) * | 1998-09-22 | 2002-11-21 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivatives |
US6147224A (en) | 1998-10-01 | 2000-11-14 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
US20030015818A1 (en) * | 1999-04-06 | 2003-01-23 | Magvire Stephen B. | Shuttle granulator |
DK1161410T3 (da) | 1999-03-08 | 2004-09-20 | Basilea Pharmaceutica Ag | Retinoidantagonister og anvendelse deraf |
AT407876B (de) | 1999-04-30 | 2001-07-25 | Georg Dr Uray | Lumineszierende 4-trifluormethyl-2-chinolinone mit langwelliger uv-absorption und ihre verwendung |
US6444668B1 (en) * | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
US6380178B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
US6319912B1 (en) | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
US6399593B1 (en) | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
US6358947B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
US6423699B1 (en) | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
US6430438B1 (en) * | 1999-05-21 | 2002-08-06 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system with atrial shock timing optimization |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
CZ2002711A3 (cs) | 1999-08-27 | 2003-11-12 | Ligand Pharmaceuticals Incorporated | Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití |
JP2003508397A (ja) | 1999-08-27 | 2003-03-04 | リガンド・ファーマシューティカルズ・インコーポレイテッド | アンドロゲンレセプターモジュレーターとしての8−置換−6−トリフルオロメチル−9−ピリド[3,2−g]キノリン化合物 |
US6172241B1 (en) | 1999-10-15 | 2001-01-09 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
US20020009498A1 (en) * | 1999-11-05 | 2002-01-24 | Guy L. Clifton | Methods and compositions for treatment of traumatic brain injury |
EP1255438A1 (en) * | 2000-01-14 | 2002-11-13 | The Procter & Gamble Company | Systems for controlling plant and flower moisture transpiration rates |
US7502003B2 (en) * | 2000-01-20 | 2009-03-10 | Real D | Method for eliminating pi-cell artifacts |
DE10002354A1 (de) * | 2000-01-20 | 2001-08-09 | Wacker Siltronic Halbleitermat | Verfahren zur Herstellung einer Halbleiterscheibe |
DE10002325A1 (de) * | 2000-01-20 | 2001-08-09 | Infineon Technologies Ag | Verfahren zum Anlaufen eines Schaltnetzteiles und Schaltnetzteil mit einer Anlaufschaltung |
EP1126513A1 (en) * | 2000-02-16 | 2001-08-22 | Semiconductor 300 GmbH & Co. KG | Process for planarization and recess etching of polysilicon in an overfilled trench |
DE10012314A1 (de) * | 2000-03-14 | 2001-09-20 | Leo Elektronenmikroskopie Gmbh | Detektorsystem für ein Korpuskularstrahlgerät und Korpuskularstrahlgerät mit einem solchen Detektorsystem |
UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
US6914548B2 (en) * | 2000-04-28 | 2005-07-05 | Mcgill University | Programmable DC voltage generator |
DE10022889B4 (de) * | 2000-05-25 | 2007-12-20 | Lurgi Zimmer Gmbh | Verfahren zum Herstellen von synthetischen Fäden aus einer Polymermischung auf Polyesterbasis |
US20020011135A1 (en) * | 2000-06-19 | 2002-01-31 | Wayne Hall | Reversible socket wrench set |
JP2002004977A (ja) * | 2000-06-26 | 2002-01-09 | Denso Corp | 流量制御装置 |
JP2002015648A (ja) * | 2000-06-28 | 2002-01-18 | Yazaki Corp | 回路遮断装置 |
JP2002014658A (ja) * | 2000-06-29 | 2002-01-18 | Nec Kansai Ltd | 液晶駆動用集積回路素子 |
JP2002100772A (ja) * | 2000-07-17 | 2002-04-05 | Toshiba Corp | 電力用半導体装置及びその製造方法 |
GB2369452B (en) * | 2000-07-27 | 2002-07-17 | Michael John Downs | Beam splitting blocks |
US20050101587A9 (en) * | 2000-08-14 | 2005-05-12 | Butler Christopher R. | Method for treating allergies using substituted pyrazoles |
JP5049447B2 (ja) * | 2000-08-14 | 2012-10-17 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換ピラゾール |
JP5140225B2 (ja) * | 2000-08-14 | 2013-02-06 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換ピラゾール |
WO2002014317A2 (en) | 2000-08-14 | 2002-02-21 | Ortho Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
US7332494B2 (en) * | 2000-08-14 | 2008-02-19 | Janssen Pharmaceutica, N.V. | Method for treating allergies using substituted pyrazoles |
EP1401801B1 (en) * | 2000-08-24 | 2006-11-02 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
MXPA03001960A (es) | 2000-09-06 | 2004-03-18 | Johnson & Johnson | Un metodo para tratar alergias. |
US7026484B2 (en) | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
US7214690B2 (en) | 2001-02-23 | 2007-05-08 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods |
EP1373204B1 (en) | 2001-03-09 | 2016-10-26 | Janssen Pharmaceuticals, Inc. | Heterocyclic compounds |
US7039575B2 (en) * | 2001-04-12 | 2006-05-02 | Ge Capital Services Structured Finance Group, Inc. | Methods and systems for the evaluation of power generating facilities |
US7138404B2 (en) * | 2001-05-23 | 2006-11-21 | Hoffmann-La Roche Inc. | 4-aminopyrimidine derivatives |
US20030000890A1 (en) * | 2001-05-29 | 2003-01-02 | Quick Nathaniel R. | Tubular membrane and method of making |
US20030013050A1 (en) * | 2001-06-26 | 2003-01-16 | Schwark Dwight W. | Coating composition containing polythiophene, film-forming binder, and solvent mixture |
US7734676B2 (en) * | 2001-06-27 | 2010-06-08 | International Business Machines Corporation | Method for controlling the number of servers in a hierarchical resource environment |
US6694235B2 (en) * | 2001-07-06 | 2004-02-17 | Denso Corporation | Vehicular relay device, in-vehicle communication system, failure diagnostic system, vehicle management device, server device and detection and diagnostic program |
US6621691B2 (en) * | 2001-07-10 | 2003-09-16 | Dell Products L.P. | Portable computer with top mounted optical drive |
ATE349463T1 (de) | 2001-07-11 | 2007-01-15 | Vertex Pharma | Verbrückte bizyklische serinproteaseinhibitoren |
GB2377780A (en) * | 2001-07-18 | 2003-01-22 | Hewlett Packard Co | Computer apparatus for implementing a workflow with data analysis |
TW524754B (en) * | 2001-07-24 | 2003-03-21 | Nano Dynamics Inc | Ink supplying cassette having under pressure regulation mechanism |
US6815101B2 (en) * | 2001-07-25 | 2004-11-09 | Ballard Power Systems Inc. | Fuel cell ambient environment monitoring and control apparatus and method |
US20030073672A1 (en) * | 2001-09-05 | 2003-04-17 | Breitenbucher J. Guy | Method for treating allergies using substituted pyrazoles |
US7138395B2 (en) * | 2002-06-10 | 2006-11-21 | The Procter & Gamble Company | Interleukin-1β converting enzyme inhibitors |
US6833635B2 (en) * | 2002-07-08 | 2004-12-21 | Artesyn Technologies, Inc. | Dual input DC-to-DC power converter |
JP2004045346A (ja) * | 2002-07-16 | 2004-02-12 | Nisshinbo Ind Inc | マイクロアレイの作製方法 |
CA2497827A1 (en) * | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
DE20301728U1 (de) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
CA2501833A1 (en) | 2002-10-11 | 2004-04-22 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
HK1055058A2 (en) | 2002-10-11 | 2003-12-05 | Ligand Pharm Inc | 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
-
2000
- 2000-08-24 US US09/649,466 patent/US6566372B1/en not_active Expired - Lifetime
- 2000-08-25 CZ CZ2002709A patent/CZ2002709A3/cs unknown
- 2000-08-25 AU AU70819/00A patent/AU782647B2/en not_active Ceased
- 2000-08-25 HU HU0204337A patent/HUP0204337A3/hu unknown
- 2000-08-25 KR KR1020027002495A patent/KR20020040791A/ko not_active Application Discontinuation
- 2000-08-25 MX MXPA02002027A patent/MXPA02002027A/es active IP Right Grant
- 2000-08-25 CN CNB008147507A patent/CN1262540C/zh not_active Expired - Fee Related
- 2000-08-25 EP EP00959507A patent/EP1212303A2/en not_active Withdrawn
- 2000-08-25 JP JP2001519677A patent/JP2003508387A/ja active Pending
- 2000-08-25 PL PL00354410A patent/PL354410A1/xx unknown
- 2000-08-25 TR TR2002/00508T patent/TR200200508T2/xx unknown
- 2000-08-25 WO PCT/US2000/023585 patent/WO2001016108A2/en active IP Right Grant
- 2000-08-25 MX MX2010002330A patent/MX338710B/es unknown
- 2000-08-25 CN CNB2005101128554A patent/CN100384823C/zh not_active Expired - Fee Related
- 2000-08-25 SK SK274-2002A patent/SK2742002A3/sk unknown
- 2000-08-25 CA CA002384435A patent/CA2384435A1/en not_active Abandoned
- 2000-08-25 BR BR0013653-0A patent/BR0013653A/pt not_active IP Right Cessation
- 2000-08-25 CN CNA2006100785318A patent/CN101029042A/zh active Pending
- 2000-08-25 IL IL14804600A patent/IL148046A0/xx unknown
-
2002
- 2002-02-06 ZA ZA200201053A patent/ZA200201053B/xx unknown
- 2002-02-25 NO NO20020912A patent/NO20020912L/no unknown
- 2002-03-21 BG BG106539A patent/BG106539A/xx unknown
- 2002-11-18 US US10/299,909 patent/US6964973B2/en not_active Expired - Lifetime
-
2005
- 2005-06-23 US US11/165,769 patent/US7696246B2/en not_active Expired - Fee Related
-
2009
- 2009-11-13 US US12/590,805 patent/US20110112084A9/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL148046A0 (en) | 2002-09-12 |
AU782647B2 (en) | 2005-08-18 |
WO2001016108A2 (en) | 2001-03-08 |
CN101029042A (zh) | 2007-09-05 |
EP1212303A2 (en) | 2002-06-12 |
ZA200201053B (en) | 2003-08-27 |
SK2742002A3 (en) | 2002-09-10 |
US20030130505A1 (en) | 2003-07-10 |
WO2001016108A3 (en) | 2001-12-20 |
US20110112084A9 (en) | 2011-05-12 |
NO20020912L (no) | 2002-04-29 |
CN100384823C (zh) | 2008-04-30 |
HUP0204337A2 (hu) | 2003-03-28 |
TR200200508T2 (tr) | 2002-09-23 |
CN1262540C (zh) | 2006-07-05 |
CN1775759A (zh) | 2006-05-24 |
JP2003508387A (ja) | 2003-03-04 |
CA2384435A1 (en) | 2001-03-08 |
PL354410A1 (en) | 2004-01-12 |
US6566372B1 (en) | 2003-05-20 |
CN1382124A (zh) | 2002-11-27 |
US20050288350A1 (en) | 2005-12-29 |
AU7081900A (en) | 2001-03-26 |
US6964973B2 (en) | 2005-11-15 |
MXPA02002027A (es) | 2003-05-19 |
MX338710B (es) | 2016-04-28 |
KR20020040791A (ko) | 2002-05-30 |
CZ2002709A3 (cs) | 2002-08-14 |
HUP0204337A3 (en) | 2003-06-30 |
BR0013653A (pt) | 2002-05-14 |
US20100069379A1 (en) | 2010-03-18 |
NO20020912D0 (no) | 2002-02-25 |
US7696246B2 (en) | 2010-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG106539A (en) | Bicyclic androgen and progesterone receptor modulator compounds and methods | |
HK1058934A1 (en) | Cyclopentanoindoles, compositions containing such compounds and methods of treatment | |
MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
EP0911321A3 (en) | Compounds for the treatment of osteoporosis | |
AP9801269A0 (en) | Prostaglandin agonists. | |
BG106550A (en) | Androgen receptor modulator compounds and methods for the production and application thereof | |
MY137040A (en) | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | |
AU3508497A (en) | Androgen receptor modulator compounds and methods | |
BG103189A (en) | Substituted 6,5-heterobicyclic derivatives | |
YU7797A (sh) | Kombinovana terapija za osteoporozu | |
BG106771A (en) | Heterocyclic substituted pyrazolones | |
AU2002326072A1 (en) | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists | |
IL148180A0 (en) | Isomeric fused pyrrolocarbazoles and isoindolones | |
CO4910163A1 (es) | Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas | |
ES2136037A1 (es) | Inhibidores de sulfamida-metaloproteasa | |
AU9102198A (en) | Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens | |
MY135916A (en) | Use of certain affinity nmda antagonists as antidepressants | |
DE60201892D1 (en) | Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist | |
IL136689A0 (en) | Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | |
MXPA04001977A (es) | Antagonistas v de receptor ccr-3. | |
YU26001A (sh) | Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora | |
ATE265853T1 (de) | Kombinationstherapeutika, enthaltend einen selektiven östrogenrezeptormodulator und prostaglandin e2 | |
WO2005017185A3 (en) | HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS | |
NZ334622A (en) | Phenozyethylamine derivatives, method of preparation, application as medicine and pharmaceutical compositions containing same which have high affinity for 5-HT1A receptors and can be used to inhibit gastric acid secretion or as an antiemetic | |
BG101431A (en) | the 2-(3,5-DIFLUOROPHENYL)-3-(4-(METHYLSULPHONYL)PHENYL-2-CYLOPENTEN-1 -ON APPLICABLE AS COX-2 INHIBITOR |